Thursday, March 26, 2026
ISSN 2765-8767
  • Home
  • Courses
  • About Us
  • Contact us
  • Support Us
  • Home
  • Courses
  • About Us
  • Contact us
  • Support Us

Atlantic releases op-ed on Indian Americans and COVID-19

On April 15, Gargi Shindé, a 43-year-old nonprofit executive, logged onto Zoom at 5 a.m. From her home in Charlotte, North Carolina, she watched her relatives huddle around a bright-yellow body bag at a crematorium in Pune, India. They were performing the final rites for Shindé’s aunt, Vijaya, who had just died from COVID-19. All she could do was watch. The bag was almost fully zipped, revealing only Vijaya’s face, which appeared tiny and blurry through Shindé’s phone. “The only contribution I had was writing an obituary,” she told me, “and I’m scared I’ll have to do another one soon.”

On top of the grief and anger she’s feeling, Shindé has been struggling to comprehend the “surreal, stark contrast” between her own safety in Charlotte—where restrictions are loosening—and the catastrophe upending life back home. Then, on Thursday, Shindé emailed to tell me that another one of her aunts had just died from COVID-19.

Over the past two weeks, tragedies like what Shindé experienced are becoming a horrific new reality for Indian Americans. Many are glued to WhatsApp through the night, checking in on relatives as India confronts one of the world’s worst coronavirus surges. Every day, India is breaking grim global pandemic records, and even these numbers may be dramatically lower than the actual toll. The situation has become so dire that it verges on apocalyptic: Hospitals are running out of beds and oxygen, and people are dying while waiting for treatment. Crematoria are so overcrowded that workers are building makeshift funeral pyres in car parks, where grieving families wait for up to 20 hours for access.

Source: Atlantic

Daily Remedy

Daily Remedy

Dr. Jay K Joshi serves as the editor-in-chief of Daily Remedy. He is a serial entrepreneur and sought after thought-leader for matters related to healthcare innovation and medical jurisprudence. He has published articles on a variety of healthcare topics in both peer-reviewed journals and trade publications. His legal writings include amicus curiae briefs prepared for prominent federal healthcare cases.

Videos

Policy Shift in Peptide Regulation

GLP-1 Drugs Have Moved Past Weight Loss. Medicine Has Not Fully Caught Up.

Glucagon-Like Peptide–Based Therapies and Longevity: Clinical Implications from Emerging Evidence

Glucagon-like peptide–based therapies are increasingly used for weight management and glycemic control, but their potential impact on long-term survival remains uncertain. The clinical question addressed in this report is whether treatment with glucagon-like peptide receptor agonists is associated with reductions in all-cause mortality and age-related morbidity beyond their established metabolic effects. This question matters because these agents are now prescribed across broad patient populations, including individuals without diabetes, and long-term exposure may influence cardiovascular, oncologic, and neurodegenerative outcomes. Understanding whether...

Read more

Join Our Newsletter!